Product Information
PAROXETINE ER 12.5 MG TABLET is a generic product labeled by Rhodes Pharmaceuticals L.P., priced at $0.4768 per EA under NDC 42858070303. Its NADAC has been published 403 times since Nov 14, 2018.
FDA first approved this application on Jun 12, 2018. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
12.5 mg/1
Manufacturer
Rhodes Pharmaceuticals L.P.NDC
42858070303
Classification
Generic
Dosage Form
TABLET, FILM COATED, EXTENDED RELEASE
Route
ORAL
Effective Date
7/22/2026
Active Ingredients
PAROXETINE HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA209293FDA Approved
6/12/2018
TE Code
AB
On Market Since
9/14/2018
Pharmacological Classes
Price Statistics
The NADAC for PAROXETINE ER 12.5 MG TABLET has been published 403 times since Nov 14, 2018, and over the history we have for it it has declined 78.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.4768 per EA |
|---|---|
| All-time high | $2.2415 (Nov 14, 2018) |
| All-time low | $0.4365 (Jul 23, 2025) |
| 52-week high | $0.5254 |
| 52-week low | $0.4433 |
| Median price | $0.8615 |
| Average price | $1.0014 |
| Largest weekly change | +48.4% (May 19, 2021) |
| Weeks tracked | 403 |
| Tracking since | Nov 14, 2018 |
1W
N/A
1M
N/A
3M
-3.3%
6M
-3.3%
1Y
-3.6%
3Y
-35.0%
5Y
-64.8%
All
-78.7%
Last surveyed Jul 29, 2026 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the PAROXETINE HYDROCHLORIDE HEMIHYDRATE market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Rhodes Pharmaceuticals L.P. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
PAROXETINE HYDROCHLORIDE HEMIHYDRATE market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Serotonin Reuptake Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of PAROXETINE ER 12.5 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for PAROXETINE ER 12.5 MG TABLET, manufactured by Rhodes Pharmaceuticals L.P., is $0.4768 per EA (NDC 42858070303), effective Jul 29, 2026.
How has the price of PAROXETINE ER 12.5 MG TABLET changed over time?
Over the history we have for it, the NADAC for PAROXETINE ER 12.5 MG TABLET has declined 78.7%. It has been tracked across 403 weekly CMS publications since Nov 14, 2018.
What are the highest and lowest recorded NADAC prices for PAROXETINE ER 12.5 MG TABLET?
Since Nov 14, 2018, the NADAC for PAROXETINE ER 12.5 MG TABLET has ranged from a low of $0.4365 (Jul 23, 2025) to a high of $2.2415 (Nov 14, 2018), with a median of $0.8615 per EA.
Are there cheaper alternatives to PAROXETINE ER 12.5 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of PAROXETINE ER 12.5 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures PAROXETINE ER 12.5 MG TABLET?
PAROXETINE ER 12.5 MG TABLET (NDC 42858070303) is labeled by Rhodes Pharmaceuticals L.P., and CMS classifies it as a generic product.